Isomaltooligosaccharides.

The alpha-1,6-linked glucose oligomers in IMO resist human digestive enzymes to a partial degree and reach the colon, where bifidobacteria carrying the right glucosidases ferment them. This is the basis for the bifidogenic effect described in the review literature. How much reaches the colon depends heavily on the degree of polymerisation of the particular product.

Lactobacilli capable of using alpha-linked glucose oligomers ferment the undigested fraction of IMO to lactate and short chain fatty acids. Pairing the substrate with an organism that can use it is the standard synbiotic design. Not all lactobacilli carry the necessary enzymes, so the fit is strain-dependent.

A combination of essential oils, Saccharomyces cerevisiae and isomaltooligosaccharides was studied together for intestinal outcomes in livestock. The design cannot separate the contribution of the IMO from the other two components. It is an animal production study, so it does not speak to what happens in a person.

Fermentation of IMO by saccharolytic organisms yields acetate and lactate, which butyrate producers take up and convert. The butyrate is made by a different set of organisms than those that first degrade the oligosaccharide. This is a chain of hand-offs rather than a direct conversion.

IMO is an alpha-linked glucan and inulin is a beta-linked fructan, so they are degraded by different enzyme sets and support partly different organisms. Blending fibre types spreads fermentation across a wider stretch of colon than either alone. The trade-off is that a blend also stacks the gas load from two sources.

Both are alpha-linked glucose polymers reaching the colon, differing in chain length and physical form. Resistant starch is granular and slow, IMO is soluble and faster. The pairing gives fermentation across a longer transit window, though it draws on overlapping degrader populations.

Human intestinal isomaltase and sucrase-isomaltase can hydrolyse a meaningful fraction of IMO in the small intestine, which is exactly why IMO's fibre status has been questioned. Adding a supplemental alpha-glucosidase increases that upper-gut breakdown further. More small intestinal digestion means less substrate reaching the colon and more absorbed glucose.

The digestible fraction of IMO is absorbed as glucose, so a product using it as a bulk sweetener contributes more available carbohydrate than a true fibre would. Chromium appears in the same product category aimed at carbohydrate handling. The pairing is a formulation choice, and the honest point is that IMO is not glycaemically inert.

Psyllium is a poorly fermented gel-forming fibre that adds stool bulk and holds water, while IMO is fermentable and adds little bulk. Combining them covers two different fibre functions in one product. They do not compete, because they are handled by entirely different routes.

Both are soluble and fermentable, but guar gum is a galactomannan fermented slowly along the colon while IMO ferments faster and more proximally. Blending them widens the stretch of colon that receives substrate. Both contribute to gas, so stacking them raises the total load.

GOS is galactose-based with beta linkages and IMO is glucose-based with alpha linkages, so different transporters and hydrolases are involved. Organisms that use one may not use the other. The practical consequence is broader coverage of the resident community than a single oligosaccharide gives.